Japan-based Takeda acquired Cambridge, Mass.-based Ariad Pharmaceuticals for $24 per share, Yahoo! Finance reports.
Here's what you should know.
1. Takeda announced the acquisition on Jan. 9, 2017.
2. The acquisition was the target of an investigation from New York City-based Faruqi & Faruqi. The law firm investigated whether Ariad properly executed fair sale practices.
3. Takeda's President and CEO Christophe Weber said, "We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD's innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area."